GlassScriptPhysician profile
Crystal Ann Terrill
NPI 1124349964
$1,582.75
in general payments reported to CMS, 2019-2025
30 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $207 · 2021: $421 · 2022: $212 · 2023: $220 · 2024: $142 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.79 |
| Education | $111.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.76 | 2020-2023 | Liletta |
| Mayne Pharma Commercial LLC | $149.05 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.51 | 2019-2024 | |
| Astellas Pharma US INC | $115.12 | 2021-2023 | Myrbetriq |
| Aspira Women'S Health INC | $113.24 | 2021 | |
| Daiichi Sankyo INC. | $93.84 | 2019-2022 | |
| Alydia Health | $66.55 | 2021 | |
| Therapeuticsmd, INC. | $53.44 | 2019-2022 | |
| Allergan, INC. | $48.84 | 2019-2020 | |
| Medtronic, INC. | $47.72 | 2021-2024 | Minimed 780g |
| Amag Pharmaceuticals, INC. | $42.16 | 2019-2020 | |
| Optumhealth Care Solutions, LLC | $36.18 | 2024-2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Avion Pharmaceuticals | $32.14 | 2019-2022 | |
| Meditrina | $28.71 | 2025 | |
| Merck Sharp & Dohme LLC | $27.41 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $27.12 | 2020-2024 | Paragard T 380a |
| Millicent US INC | $26.70 | 2024 | |
| Mylan Pharmaceuticals INC. | $24.90 | 2020 | |
| Glaxosmithkline, LLC. | $23.59 | 2024 | Pediarix, Menveo, Bexsero |
| Sumitomo Pharma America, INC. | $21.29 | 2024 | Myfembree |
| Organon LLC | $21.23 | 2022 | |
| Biogen, INC. | $20.53 | 2025 | Zurzuvae |
| Smith+Nephew, INC. | $18.81 | 2019 | |
| Hologic Sales and Service, LLC | $17.97 | 2025 | Fetal Fibronectin Enzyme Immunoassay |
| Olympus America INC. | $17.42 | 2022 | |
| Dexcom, INC. | $17.37 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $17.15 | 2025 | Mounjaro, Zepbound |
| Exeltis, USA INC. | $16.39 | 2025 | Slynd |
| Shield Therapeutics INC | $15.85 | 2025 | |
| Axsome Therapeutics, INC. | $13.76 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Terrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.